Who are the top shareholders of the Kronox Lab?

The top shareholders of Kronox Lab include promoter Jogindersingh G Jaswal with 26.39%, followed by individual investors with 20.54%, and the Negen Undiscovered Value Fund at 1.71%. Additionally, four Foreign Institutional Investors hold a combined 0.04% of the shares.

The top shareholders of Kronox Lab include the promoters, who hold the majority of the shares. The promoter with the highest holding is Jogindersingh G Jaswal, with a stake of 26.39%. Additionally, there are four Foreign Institutional Investors (FIIs) holding a combined 0.04% of the shares. The highest public shareholder is the Negen Undiscovered Value Fund, which holds 1.71%. Individual investors collectively own 20.54% of the company.

how big is Kronox Lab?

As of Jun 06, Kronox Lab Sciences Ltd has a market capitalization of 631.00 Cr, classifying it as a Micro Cap company, with recent net sales of 100.19 Cr and net profit of 25.47 Cr over the last four quarters. Shareholder's funds are valued at 66.31 Cr, with total assets of 73.61 Cr as of Mar'24.

Market Cap: As of Jun 06, Kronox Lab Sciences Ltd has a market capitalization of 631.00 Cr, which classifies it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters, which includes Mar'25, Dec'24, Sep'24, and Jun'24, is 100.19 Cr. The sum of Net Profit for the same period is 25.47 Cr. This data is based on Standalone financials.<BR><BR>Balance Sheet Snapshot: This is based on Standalone data for the reporting period of Mar'24. Shareholder's Funds are valued at 66.31 Cr, and Total Assets amount to 73.61 Cr.

Has Kronox Lab declared dividend?

Kronox Lab Sciences Ltd has declared a 5% dividend, amounting to 0.5 per share, with an ex-date of August 23, 2024. Despite the dividend declaration, total returns have been mixed, showing significant negative returns in the short term and minimal returns over longer periods.

Kronox Lab Sciences Ltd has declared a 5% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 5%<BR>- Amount per share: 0.5<BR>- Ex-date: 23 Aug 24<BR><BR>Dividend Yield: 0.29%.<BR><BR>Total Returns by Period:<BR>In the 6-month period, the price return was -16.64%, the dividend return was 0%, resulting in a total return of -16.64%.<BR><BR>For the 1-year period, the price return was 0%, the dividend return was 0.33%, leading to a total return of 0.33%.<BR><BR>In the 2-year period, both the price return and dividend return were 0%, resulting in a total return of 0.0%.<BR><BR>Over the 3-year period, there was no change in price or dividend return, maintaining a total return of 0.0%.<BR><BR>In the 4-year period, the price return and dividend return remained at 0%, resulting in a total return of 0.0%.<BR><BR>For the 5-year period, there was also no change in price or dividend return, leading to a total return of 0.0%.<BR><BR>Overall, while Kronox Lab has declared a dividend, the total returns over the various periods indicate a mixed performance, with significant negative returns in the short term and minimal returns over the longer term.

Is Kronox Lab overvalued or undervalued?

As of July 2, 2024, Kronox Lab is considered very expensive and overvalued with a PE ratio of 24.48, an EV to EBITDA of 18.54, and a Price to Book Value of 8.08, despite a year-to-date return of -15.17% compared to the Sensex's 5.54%.

As of 2 July 2024, the valuation grade for Kronox Lab has moved from does not qualify to very expensive, indicating a significant shift in its perceived value. The company is currently considered overvalued. Key ratios include a PE ratio of 24.48, an EV to EBITDA of 18.54, and a Price to Book Value of 8.08, which are notably high compared to industry norms.<BR><BR>In comparison to its peers, Kronox Lab's PE ratio is substantially lower than that of Solar Industries India Ltd. at 123.77 and Godrej Industries Ltd. at 46.63, but it remains elevated within its own valuation grade. The company's recent stock performance has been underwhelming, with a year-to-date return of -15.17%, contrasting sharply with the Sensex's positive return of 5.54% during the same period. This reinforces the notion that Kronox Lab is currently overvalued in the specialty chemicals sector.

Who are the peers of the Kronox Lab?

Kronox Lab's peers include Indokem, Nitta Gelatin, and Sudarshan Pharma, among others. Indokem has the highest 1-year return at 278.31%, while Black Rose Indus has the lowest at -25.91%, with Kronox Lab's return at 27.51%.

Peers: The peers of Kronox Lab are Indokem, Nitta Gelatin, DMCC Speciality, Jayant Agro Org., Chemcon Special., Sudarshan Pharma, Sunshield Chem., Nikhil Adhesives, Black Rose Indus, and Bhatia Colour.<BR><BR>Quality Snapshot: Excellent management risk is observed at Nitta Gelatin and Chemcon Special., while Average management risk is found at DMCC Speciality, Jayant Agro Org., Sudarshan Pharma, Sunshield Chem., Nikhil Adhesives, Black Rose Indus, and the rest. Below Average management risk is noted at Indokem and Bhatia Colour. In terms of Growth, Excellent growth is seen at Sudarshan Pharma, Good growth is found at Jayant Agro Org. and DMCC Speciality, while Below Average growth is noted at Indokem, Chemcon Special., Sunshield Chem., Nikhil Adhesives, Black Rose Indus, and the rest. Lastly, Excellent capital structure is observed at Nitta Gelatin and Chemcon Special., while Good capital structure is found at DMCC Speciality and Nikhil Adhesives, and Below Average capital structure is noted at Indokem, Sudarshan Pharma, Sunshield Chem., Black Rose Indus, and Bhatia Colour.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Indokem at 278.31%, while the peer with the lowest is Black Rose Indus at -25.91%. Kronox Lab's 1-year return of 27.51% is significantly lower than Indokem's but higher than Black Rose Indus's. Additionally, Sudarshan Pharma, Sunshield Chem., Nikhil Adhesives, and Black Rose Indus all have negative six-month returns.

What does Kronox Lab do?

Kronox Lab Sciences Ltd is a micro-cap company in the specialty chemicals industry, reporting net sales of 261 Cr and a net profit of 63 Cr for March 2025. It has a market cap of INR 711 Cr and key metrics include a P/E of 28.00 and a return on equity of 33.01%.

Overview:<BR>Kronox Lab Sciences Ltd operates in the specialty chemicals industry and is categorized as a micro-cap company.<BR><BR>History:<BR>Kronox Lab Sciences Limited was incorporated in 2008 as 'Kronox Lab Sciences Private Limited' and later converted into a Public Limited Company in 2019. The most recent quarterly results report net sales and profit for March 2025.<BR><BR>Financial Snapshot:<BR>Net Sales: 261 Cr (Quarterly Results - Mar 2025)<BR>Net Profit: 63 Cr (Quarterly Results - Mar 2025)<BR>Market Cap: INR 711 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 28.00<BR>Industry P/E: 47<BR>Dividend Yield: 0.26%<BR>Debt Equity: -0.13<BR>Return on Equity: 33.01%<BR>Price to Book: 9.27<BR><BR>Contact Details:<BR>Registrar Address: Not available.

When is the next results date for Kronox Lab?

The next results date for Kronox Lab is 11 August 2025.

The next results date for Kronox Lab is scheduled for 11 August 2025.

Is Kronox Lab technically bullish or bearish?

As of October 8, 2025, Kronox Lab's technical trend has shifted to a bearish stance with moderate strength, indicated by bearish MACD, RSI, moving averages, and underperformance compared to the Sensex.

As of 8 October 2025, the technical trend for Kronox Lab has changed from mildly bearish to bearish. The current stance is bearish with moderate strength. Key indicators driving this include a bearish MACD on the weekly timeframe, a bearish RSI on the monthly timeframe, and bearish moving averages on the daily timeframe. Additionally, the KST is bearish on the weekly, and Dow Theory indicates a mildly bearish outlook on both weekly and monthly timeframes. The stock has underperformed significantly compared to the Sensex over various periods, further supporting the bearish sentiment.

Are Kronox Lab latest results good or bad?

Kronox Lab's latest results are mixed; while they reported strong profitability with a net profit of ₹6.68 crores and improved operating margins, revenue growth has been modest, raising concerns among investors. Overall, the company shows operational efficiency but needs to accelerate revenue growth to enhance investor confidence.

Kronox Lab's latest results present a mixed picture. On one hand, the company has shown strong profitability metrics, with a net profit of ₹6.68 crores for Q2 FY26, reflecting a 6.37% increase quarter-over-quarter and a 3.24% increase year-over-year. Additionally, the operating margin improved to 33.84%, marking the highest level in the past seven quarters, which indicates effective cost management.<BR><BR>However, the revenue growth has been relatively modest, with Q2 FY26 revenue at ₹25.53 crores, only a 5.10% increase from the previous quarter and a mere 2.70% increase compared to the same quarter last year. This lack of significant top-line momentum, combined with the stock trading 35.51% below its 52-week high, has raised concerns among investors.<BR><BR>Overall, while Kronox Lab demonstrates operational efficiency and strong margins, the stagnation in revenue growth and ongoing market challenges contribute to a cautious outlook. The company's performance reflects a solid foundation but highlights the need for more substantial revenue acceleration to boost investor confidence.

How has been the historical performance of Kronox Lab?

Kronox Lab has demonstrated consistent growth over the past four years, with net sales increasing from 82.25 Cr in Mar'22 to 100.19 Cr in Mar'25, and profit after tax rising from 13.63 Cr to 25.47 Cr, reflecting strong profitability and improved cash flow. The company's total assets and liabilities also grew, indicating a stable financial position.

Answer:<BR>The historical performance of Kronox Lab shows a consistent growth in net sales and profitability over the past four years.<BR><BR>Breakdown:<BR>Kronox Lab's net sales have increased from 82.25 Cr in Mar'22 to 100.19 Cr in Mar'25, reflecting a positive growth trend. The total operating income followed a similar trajectory, rising from 82.25 Cr in Mar'22 to 100.19 Cr in Mar'25. The company's operating profit (PBDIT) also demonstrated significant growth, moving from 20.79 Cr in Mar'22 to 35.65 Cr in Mar'25, with an operating profit margin of 33.06% in the latest fiscal year. Profit before tax increased from 18.36 Cr in Mar'22 to 34.27 Cr in Mar'25, while profit after tax rose from 13.63 Cr to 25.47 Cr during the same period, resulting in a PAT margin of 25.42% in Mar'25. On the balance sheet, total assets grew from 56.46 Cr in Mar'22 to 98.43 Cr in Mar'25, with total liabilities increasing from 56.46 Cr to 98.43 Cr, indicating a stable financial position. Cash flow from operating activities improved significantly, reaching 30.00 Cr in Mar'25 compared to 9.00 Cr in Mar'22, while cash and cash equivalents at the end of Mar'25 stood at 3.00 Cr, up from 2.00 Cr in Mar'22. Overall, Kronox Lab has shown robust growth in sales, profits, and cash flow, alongside a strengthening balance sheet.

Should I buy, sell or hold Kronox Lab?

Which are the latest news on Kronox Lab?

Why is Kronox Lab falling/rising?

As of 04-Dec, Kronox Lab Sciences Ltd's stock price is rising to 138.50, reflecting a positive shift after a trend reversal. However, the long-term outlook is concerning due to a year-to-date decline of 30.44% and a lack of confidence from domestic mutual funds.

As of 04-Dec, Kronox Lab Sciences Ltd's stock price is rising, currently at 138.50, reflecting a change of 1.0 (0.73%) upward. This increase comes after a trend reversal, as the stock has gained after five consecutive days of decline. Additionally, the stock has outperformed its sector by 0.94% today, indicating a positive shift in investor sentiment.<BR><BR>Despite the recent rise, the stock has shown poor performance over longer periods, with a year-to-date decline of 30.44% and a one-year drop of 31.91%. The stock is trading below its moving averages across various time frames, which typically signals weakness. However, there has been a notable increase in investor participation, with delivery volume rising by 68.67% compared to the five-day average, suggesting growing interest among investors.<BR><BR>The company's financial metrics present a mixed picture. While it has a low debt-to-equity ratio and has seen profits rise by 19% over the past year, its net sales growth has been modest at an annual rate of 6.80% over the last five years. Furthermore, the stock's valuation appears high, with a price-to-book value of 5.7, which may deter some investors. The lack of investment from domestic mutual funds, which hold 0% of the company, could indicate a lack of confidence in the stock's future performance.<BR><BR>In summary, while Kronox Lab's stock is experiencing a rise today, the overall long-term outlook remains concerning due to significant past declines and underperformance relative to benchmarks.